Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Abouelfath is active.

Publication


Featured researches published by A. Abouelfath.


Pharmacoepidemiology and Drug Safety | 2012

Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis.

M.-A. Bernard; Jacques Benichou; P. Blin; Alain Weill; Bernard Bégaud; A. Abouelfath; Nicholas Moore; Annie Fourrier-Réglat

To determine healthcare claim patterns associated using nonsteroidal anti‐inflammatory drugs (NSAIDs) for rheumatoid arthritis (RA).


Therapie | 2013

Observation of the Long-term Effects of Lifestyle Intervention during Balneotherapy in Metabolic Syndrome

Henri Gin; Jean-Louis Demeaux; Angela Grelaud; A. Grolleau; C. Droz-Perroteau; Philip Robinson; R. Lassalle; A. Abouelfath; M.R. Boisseau; Christian Toussaint; Nicholas Moore

OBJECTIVE Estimate the effect of lifestyle adjustment activities in patients with metabolic syndrome treated by prescribed balneotherapy. METHODS Observational pilot cohort study with 12-month follow-up after multidimensional lifestyle training (physical, dietary, educational) during 3-week standard stay in the spa town of Eugénie-les-Bains. RESULTS Of 145 eligible patients, 97 were included; 63 were followed and analysable. At inclusion all had ≥3 National cholesterol education program-Adult treatment panel III (NCEP-ATPIII) criteria defining metabolic syndrome, 76.2% were female, mean age was 61.2 years. At the end of follow-up (median:10.4 months, Inter-Quartile Range: [6.7;11.4]), 48 of these 63 patients (76.2%) no longer had metabolic syndrome (95%CI [65.7;86.7]). These 48 patients without metabolic syndrome at the end of follow-up represented 49.5% of the 97 included (95%CI [39.5;59.4]). CONCLUSIONS Future studies of lifestyle interventions taking advantage of the spa environment can be expected to find least one third of patients free of metabolic syndrome at the end of 12-month follow-up in the intervention group.


Annals of Pharmacotherapy | 2009

Patterns of Laxative Use in Self-Medication

Hélène Théophile; Ghada Miremont-Salamé; A. Abouelfath; Bernard Bégaud; Françoise Haramburu

TO THE EDITOR: Laxatives have long been a typical example of selfprescribed medicines. However, in 2002, the Food and Drug Administration required removal of 2 stimulant laxative ingredients (aloe and cascara) from over-the-counter drugs, as these products were not generally recognized as safe and effective.1 The European Medicines Agency stated in 2007 that, without medical supervision, the stimulant laxatives cascara, aloe and senna should only be used on a short-term basis,2 which was already the case in France for stimulant laxatives, all recommended for a maximum of 8 to 10 days. The purpose of this study was to evaluate patterns of laxative use in self-medication in actual practice. Methods. A cross-sectional study was conducted in a random sample of community pharmacies in the Bordeaux area, in southwestern France, in accordance with the requirements of the Regional Ethics Committee. All sales of laxatives without prescription were identified during a 2week period. Characteristics of users and patterns of use were collected during a face-to-face interview by using a structured questionnaire filled out by the pharmacist for each purchase of laxative without prescription. Results. A total of 137 users of laxatives in 29 pharmacies (19% of sampled pharmacies) were identified during the study period. The mean number of self-medicating laxative users was 2.4 per pharmacy per week (range 0–10); 86.1% were female, 64.2% were known customers of the pharmacy, and the median age was 64 years (interquartile range, 46–75 y). Among individuals in the study population, 18.3% purchased more than one brand and 40.9% purchased more than one box of laxatives. Table 1 summarizes patterns of laxative use in self-medication. Laxatives were used for the purpose of weight loss by 8.0% of the study population and chronically (ie, daily and for ≥1 y) by 31.4%. Stimulant laxatives, which were the most commonly used, were used chronically (31.8%) to the same extent as other types of laxatives (30.8%). Discussion. The participating pharmacy rate was rather low but concordant with that found in other studies using no follow-up or fee.3 This study confirms data in the literature showing that laxatives are used primarily by women and the elderly.4 Although notable, the proportion of laxatives used for weight loss among the population studied could have been underestimated, since such nonapproved use is often denied. The finding that stimulant laxatives were used chronically, contrary to the current guidelines and recent regulatory decisions, highlights the poor impact of leaflet warnings. The daily use of these laxatives may be based on the erroneous concept that a daily bowel evacuation is necessary for good health. Motola et al.5 made the same observation in their study, conducted among 70 pharmacies in southern Italy. Almost half of the studied population used laxatives because they considered themselves to be constipated, despite evacuating 3 or more times per week. A large education campaign for patients regarding constipation and the proper use of stimulant laxatives would certainly be appropriate.


European Journal of Clinical Pharmacology | 2014

Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France

Julien Bezin; Antoine Pariente; R. Lassalle; C. Dureau-Pournin; A. Abouelfath; Philip Robinson; Nicholas Moore; C. Droz-Perroteau; Annie Fourrier-Réglat


British Journal of Clinical Pharmacology | 2016

Usage patterns of paracetamol in France

Mai Duong; Sinem Ezgi Gulmez; Francesco Salvo; A. Abouelfath; R. Lassalle; C. Droz; P. Blin; Nicholas Moore


British Journal of Clinical Pharmacology | 2016

Usage patterns of single‐ingredient and combined paracetamol in France

Mai Duong; Sinem Ezgi Gulmez; Francesco Salvo; A. Abouelfath; R. Lassalle; C. Droz; P. Blin; Nicholas Moore


Drug Safety | 2018

Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample

Mai Duong; A. Abouelfath; R. Lassalle; C. Droz; P. Blin; Nicholas Moore


Revue D Epidemiologie Et De Sante Publique | 2017

Définition d’un score de propension haute dimension pour comparer des patients initiant un anticoagulant oral direct ou un anti-vitamine K pour une fibrillation auriculaire non-valvulaire d’après les données du Sniiram

P. Blin; A. Abouelfath; R. Lasalle; C. Dureau-Pournin; C. Droz-Perroteau; Nicholas Moore


Revue D Epidemiologie Et De Sante Publique | 2018

Intérêt d’un score de propension haute dimension pour comparer deux traitements dans le Système national des données de santé (SNDS) ; exemple avec le dabigatran et les AVK dans la fibrillation auriculaire non valvulaire

P. Blin; R. Lassalle; A. Abouelfath; C. Dureau-Pournin; C. Droz-Perroteau; Nicholas Moore


European Heart Journal | 2018

P3851Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database

Y. Cottin; P. Blin; Jacques Benichou; C. Dureau-Pournin; A. Abouelfath; R. Lassalle; C. Droz-Perroteau; P. Mismetti; Nicholas Moore

Collaboration


Dive into the A. Abouelfath's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

P. Blin

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar

R. Lassalle

Université Bordeaux Segalen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Droz

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar

Mai Duong

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge